Our CEO joined @CNBC's at #ADASciSessions to discuss why accessibility is at the heart of the evolving weight loss market and how our once-daily oral #GLP1 aleniglipron, with potential market launch expected by 2029, is designed to reach more patients globally. cnbc.com/video/2026/06/09/st…

Data from the Phase 2b ACCESS trial of aleniglipron, our once-daily oral #GLP1 pill, has been published in Nature Medicine and was presented today at the 86th #ADASciSessions. Key findings include: ➡️Up to 16.2% body weight loss at 56 weeks with continued weight loss and no apparent plateau, and ➡️a low 10.4% overall discontinuation rate. Phase 3 remains on track for Q3 2026. Read more: ir.structuretx.com/news-rele…

The patient voice matters at every table. It guides how we partner with patients and physicians and shape programs to make a real difference for people living with #obesity. Our executive director, medical affairs & advocacy engagement shares more below. ⬇️

On #ClinicalTrialsDay, we're thinking about the participants in our studies, the investigators, coordinators, and study teams beside them, and the families who make every visit possible. Our mission is to deliver oral #smallmolecule medicines that are more scalable, manufacturable, and broadly accessible because innovation only matters if it reaches the patients it's meant to serve.

Today, we reported financial results for the first quarter ended March 31, 2026, and provided a business update. Top highlights include: 📉Positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point; 🔎Aleniglipron, amylin and combination data to be presented at the 86th #ADASciSessions ▶️Data from ACCESS OLE expected in Q3 2026, and ongoing body composition and type 2 diabetes/obesity studies expected in Q4 2026; 📊Initial data from Phase 1 SAD study of oral small molecule amylin receptor agonist ACCG-2671 and initiation of MAD study expected in Q3 2026; Read the full announcement: ir.structuretx.com/news-rele…

We’re heading to the 86th #ADASciSessions to showcase aleniglipron in multiple presentations share new data across ACCESS, including its class-leading efficacy along with tolerability and safety data for aleniglipron, plus new amylin #smallmolecule and preclinical combination data. View the details here: ir.structuretx.com/news-rele…

We continue to remember Danielle Keatley, a deeply respected and valued member of our biotech community. She had a genuine passion for our company's mission to expand access to medicines, and her presence left a lasting impact on those who worked alongside her. We'll carry her memory with us and remain committed to honoring her legacy. In her honor, a memorial fund has been established, and a celebration of life will be held on Sunday, April 26. You can find more about Danielle’s life, along with details on the memorial fund and upcoming celebration of life, here. legacy.com/legacy/danielle-k…

We’re pleased to welcome Matthew Lang, J.D. as Chief Operating Officer and General Counsel at Structure Therapeutics. With 15 years of leadership across global biopharma, his experience will support our next phase of growth as we advance aleniglipron into Phase 3. Read more: ir.structuretx.com/news-rele…

Our CEO appeared on @SquawkStreet to discuss the latest Phase 2 data for aleniglipron, our once-daily #GLP1 oral pill, which demonstrated best-in-class efficacy and off-target safety, and low, single-digit discontinuation rates. The progress we’re seeing broadly reinforces that oral approaches to #obesity are becoming effective.

Our Phase 2 ACCESS II trial data marks an important milestone for the tens of millions of people living with #obesity and the physicians who care for them. As we prepare for Phase 3, the data reinforce aleniglipron's potential to become an important and more convenient option within one of the largest global therapeutic categories.

We're pleased to announce positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with #obesity and/or overweight with at least one weight related co-morbidity. This includes 44-week data from the Phase 2 ACCESS II study and interim data from the ongoing body composition study and the ACCESS open label extension study. Read more: ir.structuretx.com/news-rele…

Today, we reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. Top highlights include: 📊Topline 44-week data from ACCESS II study with higher doses expected in Q1 2026; ▶️Aleniglipron Phase 3 initiation expected in 2H 2026; 📈Initial data from Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral #amylin compound ACCG-3535 expected in 2H 2026. Read the full announcement: ir.structuretx.com/news-rele…

We are heartbroken by the tragic passing of our dear colleague and friend. She was a remarkable leader, trusted voice and deeply valued teammate. Her impact on our organization and the lives of those around her will not be forgotten.

We’ve initiated our first-in-human Phase 1 clinical study of ACCG-2671, our lead oral #smallmolecule amylin receptor agonist for the treatment of #obesity. Read more here: ir.structuretx.com/news-rele…

We're excited to announce positive topline data from the ACCESS clinical program of aleniglipron, an orally-available, once-daily, nonpeptide small molecule agonist of the #GLP1 receptor, for the treatment of people living with #obesity and/or overweight with at least one weight-related comorbidity. These findings provide comprehensive information to move into Phase 3 development and reinforce aleniglipron’s potential to become a backbone oral small molecule therapy for obesity—one that is accessible, scalable, and combinable. Read more: ir.structuretx.com/news-rele…

Our team members in Shanghai joined in the spirit of friendly competition at the Shanghai J.P. Morgan Corporate Challenge! Following our U.S. team’s debut at the San Francisco event earlier this year, our Shanghai colleagues took to the course to continue the celebration of teamwork, wellness, and community that defines Structure. It was a day filled with energy and connection, reminding us that no matter where we are in the world, we’re all part of the same team striving toward shared goals. #JPMCC

It was an honor to host patient advocates and @ObesityAction board members Jason Krynicki and Michele Tedder at our U.S. office to share their experiences and perspectives on the importance of access to care, addressing weight bias and its impact on mental health, and ensuring fair representation for people living with #obesity. Their stories and tireless advocacy remind us why continued dialogue, understanding, and innovation are essential to improving care for those living with obesity. We’re deeply grateful for their time and openness.

In recognition of both #WorldDiabetesDay and #AmericanDiabetesMonth, our teams across the U.S. and Shanghai came together to raise awareness and promote healthy living. From wear blue days and wellness walks to Tai Chi, nutrition-focused lunch and learns, our team members connected through movement, mindfulness, and education. We extend our special thanks to Athena Philis-Tsimikas, M.D., a specialist in endocrinology, diabetes, and metabolism, for sharing her valuable insights on diabetes health with us. These moments not only strengthened our commitment to supporting those affected by #diabetes, but also reminded us of the importance of balance, access, and care in everyday life.

On #WorldDiabetesDay, we recognize the global impact of diabetes and the need for accessible, effective treatments. Explore this year’s theme, “Diabetes and the Workplace”, and how equitable access to care can make a difference: worlddiabetesday.org/